CombiGene AB (publ)

Stockholm Stock Exchange COMBI.ST

CombiGene AB (publ) EBITDA for the year ending December 31, 2023: USD -3.49 M

CombiGene AB (publ) EBITDA is USD -3.49 M for the year ending December 31, 2023, a -523.54% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

CombiGene AB (publ) EBITDA for the year ending December 31, 2022 was USD -559.34 K, a -121.56% change year over year.
CombiGene AB (publ) EBITDA for the year ending December 31, 2021 was USD 2.59 M, a 183.39% change year over year.
CombiGene AB (publ) EBITDA for the year ending December 31, 2020 was USD -3.11 M, a -76.91% change year over year.
CombiGene AB (publ) EBITDA for the year ending December 31, 2019 was USD -1.76 M, a -18,774.85% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

Stockholm Stock Exchange: COMBI.ST

CombiGene AB (publ)

CEO	Mr. Peter Ekolind
IPO Date	May 25, 2015
Location	Sweden
Headquarters	Agavagen 52A
Employees	10
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Lipigon Pharmaceuticals AB to develop a gene therapy treatment for partial lipodystrophy; and with Spark Therapeutics to develop adeno-associated virus (AAV) based gene therapies. CombiGene AB (publ) was founded in 1999 and is headquartered in Lidingö, Sweden.

Key trends

Past 5 years